Skip to content

Phil Skolnick

6 papers in the library · 240 citations · publishing 1991-2012

Papers

Sort Most recent Most cited

The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.

Neuropharmacology January 2012 Jesse S O Lindholm, Henri Autio, Liisa Vesa et al.

Accumulating evidence suggests that biogenic amine-based antidepressants act, at least in part, via regulation of brain-derived neurotrophic factor (BDNF) signaling. Biogenic amine-based antidepressants increase BDNF synthesis and activate its signaling pathway through TrkB receptors. Moreover, the antidepressant-like effects of these molecules are abolished in BDNF deficient mice....

Glutamate-based antidepressants: 20 years on.

Trends in pharmacological sciences November 2009 Phil Skolnick, Piotr Popik, Ramon Trullas

Depression is a chronic recurring illness that affects more than 120 million people worldwide. Drugs increasing the synaptic availability of serotonin and norepinephrine (biogenic amine-based agents) have been used to treat depression for more than 50 years. However, significant symptom improvement requires > or =2-4 weeks of treatment and a first course of therapy provides symptom relief to...

Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors.

European Journal of Pharmacology August 8, 1996 Richard T. Layer, Phil Skolnick, C M Bertha et al. 48 citations

Based on both preclinical findings and anecdotal evidence in man, the psychoactive indole alkaloid ibogaine has been suggested to have anti-addictive properties. Previous studies indicate that blockade of NMDA receptors may mediate at least some of the putative anti-addictive actions of ibogaine. The potencies of a series of ibogaine analogs to inhibit...

NMDA antagonist properties of the putative antiaddictive drug, ibogaine.

Journal of Pharmacology and Experimental Therapeutics November 1, 1995 Piotr Popik, Richard T. Layer, Linda H. Fossom et al. 100 citations

Both anecdotal reports in humans and preclinical studies indicate that ibogaine interrupts addiction to a variety of abused substances including alcohol, opiates, nicotine and stimulants. Based on the similarity of these therapeutic claims to recent preclinical studies demonstrating that N-methyl-D-aspartate (NMDA) antagonists attenuate addiction-related phenomena, we examined the NMDA...

DOI: 10.1016/s0022-3565(25)12125-3 (opens in new tab) Nmda receptor Pharmacology Dizocilpine Antagonist +3

The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.

Psychopharmacology May 1, 1994 Piotr Popik, Richard T. Layer, Phil Skolnick 92 citations

Ibogaine is a putative anti-addictive drug with potential efficacy for the treatment of opiate, stimulant, and alcohol abuse. We now report ibogaine is a competitive inhibitor (Ki, 1.01 +/- 0.1 microM) of [3H]MK-801 binding to N-methyl-D-aspartate (NMDA) receptor coupled cation channels. Since MK-801 can attenuate the development of tolerance to morphine and alcohol as well as sensitization to...

A rapid method for evaluating the behavioral effects of phencyclidine-like dissociative anesthetics in mice.

Psychopharmacology 1991 G E Evoniuk, R P Hertzman, Phil Skolnick

A simple and rapid method for detecting the behavioral effects of phencyclidine and related dissociative anesthetics is described. Dissociative anesthetics such as phencyclidine (PCP) and dizolcipine, which bind with high affinities at N-methyl-D-aspartate (NMDA) coupled cation channels ("PCP receptors"), produced a dose-related increase in the percentage of mice that fell from a 1.5 cm deep...